Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;58(8):2308-2316.
doi: 10.1002/ppul.26485. Epub 2023 May 24.

Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis

Courtney Gushue  1   2   3 , Mariah Eisner  3   4 , Shasha Bai  4 , Terri Johnson  1   3 , Melissa Holtzlander  1   2   3 , Karen McCoy  1   2   3 , Shahid Sheikh  1   2   3
Affiliations

Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis

Courtney Gushue et al. Pediatr Pulmonol. 2023 Aug.

Abstract

Background: In people with cystic fibrosis (pwCF), the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, such as Elexacaftor-Tezacaftor-Ivacaftor (ETI), on structural changes in the lungs is unclear.

Objective: To determine the impact of ETI on clinical parameters and on structural lung disease as measured by the changes in the chest computed tomography (CT) scans in pwCF.

Methods: Percent predicted forced expiratory volume in one second (ppFEV1), body mass index (BMI), and microbiologic data were collected at initiation and 3-month intervals for 1 year. Chest CT scans before starting ETI therapy (baseline) and at 1-year on ETI therapy were compared by two pulmonologists independently.

Results: The sample size was 67 pwCF, 30 (44.8%) males, median age of 25 (16, 33.5) years. Significant increases in ppFEV1 and BMI observed by 3 months of ETI therapy persisted throughout 1 year of ETI therapy (p < 0.001 at all-time points for both). After 1 year on ETI, pwCF had significant reductions in Pseudomonas aeruginosa (-42%) and MRSA (-42%) positivity. None of the pwCF had worsening of chest CT parameters during 1 year of ETI therapy. Comparing chest CT findings at baseline and at 1-year follow-up, bronchiectasis was present in 65 (97%) pwCF and at 1-year follow-up decreased in 7 (11%). Bronchial wall thickening 64 (97%), decreased in 53 (79%). Mucous plugging in 63 (96%), absent in 11 (17%), and decreased in 50 (77%). Hyperinflation/air trapping in 44 (67%), decreased in 11 (18%), absent in 27 (44%) CONCLUSIONS: ETI significantly improved clinical outcomes and lung disease as documented by improvement in chest CT scans.

Keywords: bronchiectasis; chest computed tomography; cystic fibrosis.

PubMed Disclaimer

References

REFERENCES

    1. US CF Foundation, Johns Hopkins University, the Hospital for Sick Children. The clinical and functional translation of CFTR (CFTR2). 2011. http://cftr2.org
    1. Cystic Fibrosis Foundation. Patient Registry: Annual Data Report, 2012. Cystic Fibrosis Foundation; 2013. http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegist...
    1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891-1904.
    1. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161:233-241.
    1. Farinha CM, Amaral MD. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol. 2005;25:5242-5252.